OnKure Therapeutics (OKUR) reprices executive stock options and grants 150,000 new options
Rhea-AI Filing Summary
OnKure Therapeutics, Inc. reported that President and CEO Nicholas A. Saccomano received a grant of stock options for 150,000 shares of Class A Common Stock on August 7, 2026, with an exercise price of $4.14 per share and vesting in equal monthly installments over 48 months starting September 7, 2026, subject to continued service.
The company also implemented a one-time stock option repricing effective August 7, 2026 for options with exercise prices of at least $10.00 per share. Several of the CEO’s existing options with exercise prices of $21.20, $13.99, and $18.20 per share were reported as dispositions to the issuer and regrants at an amended exercise price of $4.14 per share. Footnotes state that there was no change to the vesting schedules, expiration dates, or number of shares underlying the repriced options, and that a "Retention Period" runs from August 7, 2026 until the earlier of February 7, 2028 or a Change in Control, during which early exercise of repriced options requires payment of the original higher exercise price.
Positive
- None.
Negative
- None.
Insider Trade Summary
11 transactions reported
Mixed
11 txns
Insider
Saccomano Nicholas A
Role
President and CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Employee Stock Option (right to buy) F1 | 150,000 | $0.00 | $0.00 |
| Disposition | Employee Stock Option (right to buy) F3, F4, F2 | 2,359 | -- | -- |
| Grant/Award | Employee Stock Option (right to buy) F3, F4, F2 | 2,359 | -- | -- |
| Disposition | Employee Stock Option (right to buy) F3, F4, F5 | 1,485 | -- | -- |
| Grant/Award | Employee Stock Option (right to buy) F3, F4, F5 | 1,485 | -- | -- |
| Disposition | Employee Stock Option (right to buy) F3, F4, F2 | 8,449 | -- | -- |
| Grant/Award | Employee Stock Option (right to buy) F3, F4, F2 | 8,449 | -- | -- |
| Disposition | Employee Stock Option (right to buy) F3, F4, F2 | 16,898 | -- | -- |
| Grant/Award | Employee Stock Option (right to buy) F3, F4, F2 | 16,898 | -- | -- |
| Disposition | Employee Stock Option (right to buy) F3, F4, F6 | 542,232 | -- | -- |
| Grant/Award | Employee Stock Option (right to buy) F3, F4, F6 | 542,232 | -- | -- |
Holdings After Transaction:
Employee Stock Option (right to buy) — 721,423 shares (Direct)
Footnotes (6)
- F1. 1/48th of the shares subject to the option shall vest on September 7, 2026 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
- F2. All of the shares subject to this option are fully vested and exercisable as of the date hereof.
- F3. The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date.
- F4. Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options.
- F5. 1/48th of the shares subject to the option vested on May 1, 2023 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
- F6. 1/36th of the shares subject to the option vested on November 4, 2024 and 1/36th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
Key Figures
New option grant: 150,000 shares
New exercise price: $4.14 per share
Repricing threshold: $10.00 per share
+5 more
8 metrics
New option grant
150,000 shares
Options for Class A Common Stock granted to CEO on August 7, 2026
New exercise price
$4.14 per share
Exercise price for new CEO grant and repriced options
Repricing threshold
$10.00 per share
Applies to options with exercise prices equal to or greater than this level
Original exercise price
$21.20 per share
One of the CEO’s options subject to repricing and regrant
Original exercise price
$13.99 per share
Several CEO options subject to repricing and regrant
Original exercise price
$18.20 per share
CEO option subject to repricing and regrant
Retention Period end date
February 7, 2028
Latest date through which premium exercise price may apply before Change in Control
Option grant expiration
August 6, 2036
Expiration date for the new 150,000-share CEO option grant
Key Terms
Option Repricing, Retention Period, Change in Control, Class A Common Stock, +1 more
5 terms
Option Repricing financial
"The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing")"
Retention Period financial
"the option holder will be required to pay a premium exercise price ... through which the option holder must remain in service to the Issuer"
Change in Control financial
"ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
Class A Common Stock financial
"the closing price of the Issuer's Class A Common Stock on the Effective Date"
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
fully vested and exercisable financial
"All of the shares subject to this option are fully vested and exercisable as of the date hereof"
FAQ
What stock option grant did OKUR’s CEO receive on August 7, 2026?
Nicholas A. Saccomano received of Class A Common Stock at an exercise price of $4.14 per share, vesting in 48 equal monthly installments starting September 7, 2026, subject to continued service.
What is the one-time option repricing disclosed by OnKure Therapeutics (OKUR)?
OnKure implemented a one-time stock option repricing effective August 7, 2026 for options with exercise prices of $10.00 or more per share, reducing the exercise price of affected options, including the CEO’s, to $4.14 per share.
How were Nicholas Saccomano’s existing OKUR options affected by the repricing?
Certain fully vested options with exercise prices of $21.20, $13.99, and $18.20 per share were reported as dispositions and regranted at an amended exercise price of $4.14, with no change to vesting schedules, expiration dates, or share counts.
Were any of the repriced OKUR options unvested as of the Form 4 date?
Footnotes state that some options are already fully vested and exercisable, while others continue vesting monthly under prior schedules (for example, 1/48th or 1/36th monthly), with those vesting terms unchanged by the repricing.
AI-generated analysis. How Rhea-AI works. Not financial advice.
